Ergocalciferol in Chronic Kidney Disease - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

December 11, 2006

Last Updated Date

December 11, 2006

Start Date ^†

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

No Changes Posted

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Ergocalciferol in Chronic Kidney Disease

Official Title ^†

The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4

Brief Summary

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Detailed Description

Study Phase

Study Type ^†

Observational

Study Design ^†

Longitudinal, Defined Population, Retrospective Study

Condition ^†

Chronic Kidney Disease

Intervention ^†

Study Arms / Comparison Groups

Publications *

Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59-68.

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.

Exclusion Criteria:

Patients who are on any form of active vitamin treatment

Gender

Both

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00411294

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Saint Louis VA Medical Center

Collaborators ^††

Investigators ^†

Principal Investigator:

Ziyad Al-Aly, M.D.

VAMC-Saint Louis

Information Provided By

Saint Louis VA Medical Center

Verification Date

December 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.